Navigation Links
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Date:2/11/2008

ll receive the PROMUS Stent and half will receive either the Cypher or the Endeavor Stent to attain a 2:1:1 ratio of PROMUS, Cypher, and Endeavor Stents respectively. The primary endpoint of the registry will be the rate of major cardiac events (cardiac death, all myocardial infarction and target vessel revascularization) at 12 months.

The PROMUS, Cypher and Endeavor Stents have previously been investigated in randomized clinical trials. Twelve-month data from the SPIRIT III Trial, presented in October 2007 at the Transcatheter Cardiovascular Therapeutics conference in Washington, confirmed earlier positive clinical results for the XIENCE V (PROMUS) Stent. This trial compared XIENCE V (PROMUS) with the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Stent, demonstrating non-inferiority in the primary endpoint of in-segment late loss at eight months with no safety concerns at 12 months.

Boston Scientific is the first company to offer European physicians and their patients a choice of two distinct drug-eluting stent platforms: TAXUS and PROMUS.

TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies. Endeavor is a trademark of Medtronic Vascular Incorporated. Cypher is a trademark of Cordis Corporation, a Johnson & Johnson company.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estim
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
2. Boston Scientific to Participate in Merrill Lynch Conference
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
7. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
8. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
9. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Cytokinetics, Incorporated (Nasdaq: ... quarter of 2015 were $4.4 million, compared to $8.0 million ... for the first quarter was $8.9 million, or $0.23 per ... loss for the same period in 2014, of $8.7 million, ... March 31, 2015, cash, cash equivalents and investments totaled $117.5 ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Oct. 5 ISTO Technologies, Inc. (ISTO), an  orthobiologics ... today the completion of patient enrollment in the Phase ... formulation of juvenile chondrocytes designed for the treatment of ... at two clinical sites. All patients enrolled in the ...
... the many pressing concerns of the day, fear of plague ... for those whose responsibility it is to combat bioterrorism, plague ... include scientists like medical researcher Steve Smiley, whose lab at ... will protect the public against weaponized forms of plague. The ...
... AMGN ) today announced that results from ... evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or ... colorectal cancer (mCRC), respectively, were published online in the ... "Both studies demonstrated that Vectibix administered with chemotherapy significantly ...
Cached Biology Technology:ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... While many bacteria exist as aggressive pathogens, causing diseases ... toxic shock syndrome, others play a less malevolent role ... a new study, Cheryl Nickerson and her group at ... including Tom Van de Wiele and lead author Rosemarie ...
... , adds to our understanding of the role of stem and ... and treatment of cancer. , While stem cells are known to ... difficult to isolate. The new findings show that an antibody developed ... , Professor Pera, program leader for Stem Cells Australia and Chair ...
... Manchester have uncovered how the internal mechanisms in nerve ... avenues in the investigation of neurodegenerative diseases by analysing ... Prokop and his team at the Faculty of Life ... thin cable-like extensions of nerve cells that wire the ...
Cached Biology News:Beneficial bacteria may help ward off infection 2Beneficial bacteria may help ward off infection 3Beneficial bacteria may help ward off infection 4Beneficial bacteria may help ward off infection 5Stem cell research aids understanding of cancer 2Cell research opens new avenues in combating neurodegenerative diseases 2Cell research opens new avenues in combating neurodegenerative diseases 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MW5...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: